Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tyche IndustriesBOM:532384 +2.74%72 EBITDA Margin % is 6.22% as of Jun. 2026, which is 74% below its 10-year median of 24.17. GuruFocus rates BOM:532384 with a GF Score™ of 72/100 and a GF Value™ of ₹108.23 (Fairly Valued). The stock has 3 warning signs investors should review. Among 957 Drug Manufacturers companies, Tyche Industries ranks better than 60.19% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tyche Industries's EBITDA for the
three
months ended in Jun. 2026 was ₹5.7 Mil. Tyche Industries's Revenue for the
three
months ended in Jun. 2026 was ₹91.0 Mil. Therefore, Tyche Industries's EBITDA margin for the quarter that ended in Jun. 2026 was 6.22%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tyche Industries EBITDA Margin % Related Terms
Tyche Industries EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tyche Industries's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tyche Industries's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tyche Industries EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tyche Industries's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tyche Industries's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tyche Industries (BOM:532384) has a EBITDA Margin % of 6.22% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tyche Industries and its competitors. This is 74% below median its historical median of 24.17. Over the past decade, Tyche Industries' EBITDA Margin % has ranged from 16.62 to 36.38. According to the industry distribution chart, Tyche Industries ranks #381 out of 957 companies in the Drug Manufacturers industry, placing it in the top 39.8%.
Is Tyche Industries' EBITDA Margin % too high?
Tyche Industries' current EBITDA Margin % of 6.22% is 74% below median its 10-year median of 24.17. Over the past 10 years, this metric has ranged from a low of 16.62 to a high of 36.38. The Drug Manufacturers industry median EBITDA Margin % is 12.60. Tyche Industries' value of 6.22% is 50.6% below this industry median. Based on the distribution chart, Tyche Industries ranks #381 out of 957 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tyche Industries has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tyche Industries' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tyche Industries ranks #381 out of 957 companies for EBITDA Margin %. This puts Tyche Industries in the upper half of its industry. The industry median EBITDA Margin % is 12.60. Tyche Industries' value of 6.22% is 50.6% below this benchmark. Historically, Tyche Industries' own EBITDA Margin % has ranged from 16.62 to 36.38 over the past decade. While the company's 10-year median is 24.17 vs. the industry median of 12.60, Tyche Industries has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.60, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tyche Industries's current EBITDA Margin % of 6.22% is 50.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tyche Industries and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tyche Industries's current EBITDA Margin % is 6.22%, which is 74% below median its own 10-year median of 24.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyche Industries stock overvalued right now?
Based on GuruFocus' analysis, Tyche Industries (BOM:532384) is currently considered Fairly Valued. The stock's GF Value™ is ₹108.23, compared to a current price of ₹106.85 — trading 1.3% below its estimated fair value. The current EBITDA Margin % is 6.22%, which is 74% below median its 10-year median of 24.17 and 50.6% below the Drug Manufacturers industry median of 12.60. Tyche Industries' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tyche Industries (BOM:532384), the current EBITDA Margin % is 6.22% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tyche Industries (BOM:532384) Overvalued in 2026?
Based on GuruFocus' analysis, Tyche Industries stock appears to be undervalued.
The current stock price of ₹106.85 is trading 1.3% below its estimated GF Value™ of ₹108.23.
GuruFocus considers Tyche Industries to be Fairly Valued.
Key valuation signals for BOM:532384:
EBITDA Margin %: 6.22% (74% below median its 10-year median of 24.17)
GF Value™: ₹108.23 vs. price of ₹106.85 (1.3% below fair value)
Industry Position: 50.6% below the Drug Manufacturers median (#381 of 957)
No single metric tells the full story. See the BOM:532384 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tyche Industries Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing of bulk drug intermediates. Geographically, it derives a majority of its revenue from the Export business. The company is a manufacturer in India of Glucosamine Hydrochloride and corresponding sodium and potassium salts which are mainly exported to the USA and Europe. Its business areas include API, Intermediates, Chiral Intermediates, Nutraceuticals, and CDMO. It operates in a single segment namely the manufacture of bulk drugs intermediates.
72GF Score
Get the complete analysis for BOM:532384
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532384 has been successfully added to your 
